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Abstract
Glucose-induced augmented vascular endothelial growth factor (VEGF)
production is a key event in diabetic retinopathy. We have previously
demonstrated that downregulation of miR-200b increases VEGF, mediating
structural and functional changes in the retina in diabetes. However, mechanisms
regulating miR-200b in diabetes are not known. Histone methyltransferase
complex, Polycomb Repressive Complex 2 (PRC2), has been shown to repress
miRNAs in neoplastic process. We hypothesized that, in diabetes, PRC2
represses miR-200b through its histone H3 lysine-27 trimethylation mark. We
show that human retinal microvascular endothelial cells exposed to high levels of
glucose regulate miR-200b repression through histone methylation, and that
inhibition of PRC2 increases miR-200b while reducing VEGF. Furthermore,
retinal tissue from animal models of diabetes, showed increased expression of
major PRC2 components, demonstrating in vivo relevance. This research
established a repressive relationship between PRC2 and miR-200b, providing
evidence of a novel mechanism of miRNA regulation through histone
methylation.

Keywords: Polycomb Repressive Complex 2, microRNA-200b, vascular
endothelial growth factor, retinal endothelial cells
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Parts of this chapter have been adapted from the following publications: 1. Ruiz, M.A.
& Chakrabarti, S. MicroRNAs: The Underlying Mediators of Pathogenetic Processes in Vascular
Complications of Diabetes. Can. J. Diabetes. 37, 339-344 (2013). and 2. Feng, B., Ruiz, M.A.
& Chakrabarti, S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications.
Can. J. Physiol. Pharmacol. 91, 213-220 (2013).
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1.1 Diabetes Mellitus
Diabetes mellitus is a metabolic disorder characterized by impaired
glucose utilization. It is defined as an absolute or relative deficiency of insulin,
leading to hyperglycemia (1). There are two major types of diabetes, which are
distinct in both their etiology and treatment strategy. Type 1 diabetes is also
known as juvenile-onset diabetes because patients typically present with glucose
utilization problems in their youth (2). The etiology of type 1 diabetes is believed
to result from auto-immune destruction of the beta-cells of the pancreas, which
function normally to secrete insulin in response to elevations in blood glucose
levels. As a result, these patients have an absolute lack of insulin.
Supplementation of exogenous insulin is the major treatment strategy for these
patients, and continual blood glucose monitoring and insulin administration with
pumps have allowed these patients to live relatively normal lives. Conversely,
patients with type 2 diabetes present at middle to late age, although this trend is
changing as we see more type 2 diabetes in children and young adults.
Etiologically, type 2 diabetes is believed to result from lifestyle habits, such as
diets high in carbohydrates and lack of physical exercise. Obesity is well linked to
insulin resistance. As a result, the pancreas must secrete insulin at a much more
rapid rate than in healthy patients (2,3). Eventually the beta-cells become
exhausted, resulting in impaired insulin secretion in combination with insulin
resistance. Medications may be necessary to treat type 2 diabetes. For example
metformin is commonly prescribed to type 2 patients and functions to improve
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insulin sensitivity. In patients who have severe type 2 diabetes with very difficult
to control blood glucose levels, insulin supplementation may be required.
While management of blood glucose levels has improved, regardless of
whether a patient has type 1 or type 2 diabetes they remain susceptible in the
long term to hyperglycemia-induced complications (4,5,6). These include diabetic
retinopathy, cardiomyopathy, nephropathy and others. These complications can
reduce the quality of the life of patients with diabetes and can even lead to early
death. Investigating how hyperglycemia causes signaling changes at a cellular
level can lead to new treatment strategies to prevent these complications.

1.2 Epidemiology
Incidence of diabetes is a growing phenomenon in recent years and
affects both the developed and undeveloped world. The World Health
Organization (WHO) estimates that more than 347 million people worldwide have
diabetes (7). In the United States, the incidence of diabetes in individuals older
than 18 years old has increased by three fold since 1980 (8). Indeed, diabetes is
no longer a disease of the young (type 1) or of the elderly (type 2). The incidence
of both type 1and type 2 diabetes has increased in the adolescent population and
working age population, highlighting the growing problem of diabetes in society
(9,10).
In Canada, the growth of diabetes is more modest than in the United
States but is significant none-the-less. Nearly 2.85 million Canadians are
estimated to be currently living with diabetes, either diagnosed or undiagnosed.
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Since 1999, the prevalence of diabetes in Canada has increased by 70% (8).
Type 1 diabetes remains the most prevalent type of diabetes in youth, however
type 2 incidence is growing. Canadians with diabetes are at 3 times greater risk
for cardiovascular disease, 12 times greater risk for end-stage renal disease and
20 times greater risk for limb amputation compared to healthy individuals.
Overall, diabetics have two fold increased risk of mortality. Research into
pathogenic signaling mechanisms involved in diabetes is necessary to develop
new treatment strategies to maintain the quality of life of patients with diabetes,
as well as to prevent diabetes-associated early death.

1.3 Diabetic Retinopathy and Pathogenic Signaling
Diabetic retinopathy is a microvascular complication of diabetes and a
leading cause of vision loss (11). In early diabetic retinopathy, hyperglycemia
induces the expression of vasoactive and inflammatory factors that increase
retinal capillary permeability, causing macular edema, and contributing to
pericyte and endothelial cell loss (4). Extracellular matrix (ECM) proteins also are
increased, contributing to basement membrane thickening (12). As diabetic
retinopathy progresses, microaneurysms develop and new vessels are formed.
New vessels may lead to bleeding and tractional retinal detachment, leading to
vision loss. Sustained hyperglycemia, elevated blood pressure and abnormal
plasma lipids are all important risk factors in the progression of chronic diabetic
complications including retinopathy. However large scale studies in both types of
diabetes, such as the Diabetes Control and Complications Trial (DCCT), the
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Epidemiology of Diabetes Interventions and Complications (EDIC) and the United
Kingdom Prospective Diabetes Study (UKPDS), have shown that hyperglycemia
is the main factor in the development of microvascular complications (13,14,15).
Intensive glycemic control is important to delay the onset and progression of
diabetic retinopathy, however this cannot always be achieved.

1.3.1 Intracellular signaling events
There are numerous signaling events and pathways that are involved in
altering the expression of vasoactive factors like vascular endothelial growth
factor (VEGF). Chronic, poorly controlled glucose first leads to signaling changes
in endothelial cells of the eye. Endothelial cells are particularly susceptible to
hyperglycemcia-induced damage due to their constitutive expression of glucose
transporter 1 (GLUT-1) (16,17,18). As a result, elevated glucose first causes
signaling changes in these cells, which manifests in altered signals to other cell
types in target organs.
A number of mechanisms are involved in hyperglycemia-induced damage.
Increased intracellular glucose increases protein glycosylation and leads to
production of advanced glycation end products (AGEs), which disrupt protein
signaling and trafficking (19). Furthermore, excessive intracellular glucose
becomes shunted down other metabolic pathways, such as the Polyol pathway.
This metabolic pathway reduces nicotinamide adenine dinucleotide phosphate
(NADPH) levels and impairs the reducing capability of the cell, resulting in
increased reactive oxygen species (ROS) (20,21). ROS is particularly damaging
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in diabetes where defective antioxidant activity (ie. MnSOD) exacerbates
damage to the retina. ROS stimulate the generation of intracellular signals and
activate pathways such as protein kinase C (PKC), c-Jun-N-terminal kinase
(JNK), and p38 mitogen-activated protein kinase (MAPK). These pathways
induce numerous functional changes; including endothelial dysfunction mediated
through altered endothelial nitric oxide synthase (eNOS) activity and enhanced
superoxide production (22,23).
Signaling cascades from metabolic changes converge in the nucleus as
activation of various transcription factors. For example, forkhead box O (FOXO)
and nuclear factor κB (NF-κB), which can mediate the effects of ROS through
regulation of gene transcription of inflammatory and antioxidant genes (24).
Oxidative stress also causes DNA damage and together activates DNA repair
enzymes, transcription factors, and transcription co-activators in endothelial cells.
The activated nucleotide excision repair enzymes include excision repair cross
complimenting 1 (ERCC1), ERCC4 (also known as Xeroderma Pigmentosum
complementation group F) and poly(ADP-ribose) polymerase (PARP) (25). In
parallel, there is augmented production of histone acetyl transferase p300 and
alterations of histone deacetylases including the class III deacetylases, the
sirtuins (26,27,28). Abnormal chromatin modifications, such as acetylation,
methylation, phosphorylation, sumoylation, and ubiquitination, occur at specific
residues in the N-terminal tails of histones and further modulate gene expression
(29). Altogether, these changes in the nucleus alter the expression of various
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genes associated with diabetic complications, which further mediate the organ’s
response to hyperglycemic conditions.

1.3.2 Transcriptional changes and extracellular consequences
The functional consequence of the altered signaling events in diabetes is
increased transcription of multiple vasoactive factors and ECM proteins, which
are involved in the development and progression of chronic diabetic
complications. Inflammatory and angiogenic cytokines elevated in diabetes signal
to increase permeability and proliferation in the retina. These mediators include
vascular endothelial growth factor (VEGF), endothelin (ET-1), interleukins (ILs)
and other factors (30,31,32). Accumulation of ECM proteins, such as fibronectin
(FN) or collagen, thickens the basement membrane and further contributes to
vascular dysfunction and increased ocular permeability (12). As a result, vessel
integrity is compromised and there is greater risk of microaneurysm and
hemorrhage, which occur commonly in diabetic retinopathy. Over time the altered
microenvironment induced by hyperglycemia changes and deteriorates the
structure of the retina, leading to decreased function and vision loss.

1.3.3 Current treatment strategies
Maintaining tight glycemic control with medications and lifestyle changes
has been the major therapeutic strategy and has been shown to prevent or slow
down the development of diabetic retinopathy (33). However, some patients, still
experience elevated glucose levels and thus remain susceptible to diabetic
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retinopathy (4). Research into key pathogenic targets that mediate diabetic
retinopathy has uncovered an important role of VEGF. VEGF is a growth factor
that is elevated in the eye in diabetes, which has been shown at both mRNA and
protein levels (34,35,36,37). VEGF causes increased vessel permeability in the
early stages of diabetic retinopathy, and mediates endothelial cell migration and
neovascularization in the late stages of diabetic retinopathy. Targeted therapy to
inhibit VEGF has been a leading strategy for years in the treatment of diabetic
retinopathy (38,39).
Targeted inhibitory therapy against VEGF receptor using a monoclonal
antibody has also been shown to be effective in preventing microaneurysm
formation and improving visual acuity in patients with diabetic retinopathy
(38,39,40,41). While VEGF-antibody has shown efficacy in both of these aspects,
pharmacological therapy is not effective for all patients. For example, 40% of
patients show no improvements in visual acuity following VEGF-antibody
treatment (41). It is also invasive, as these patients must have eye injections
monthly for one to three years. Furthermore, in Ontario the current cost of VEGFantibody treatment is over $1,500 per injection, which is not funded by the
provincial drug plans (42). As a result, this treatment carries a high cost to both
the health care system and the patient. With diabetes becoming an epidemic
across the developed and underdeveloped world, research into additional
therapies is needed to improve our understanding of the pathogenic mechanisms
of diabetic retinopathy, as well as to deliver a more efficacious treatment to more
people.
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1.4 microRNAs
Recent research has uncovered an underlying layer of microRNA (miRNA)
involvement in most biologic processes and several diseases, such as cancer or
diabetes. miRNAs, a group of noncoding RNAs, are well-studied epigenetic
elements and have shown important interactions in many pathogenetic
processes. miRNAs are post-transcriptional regulators of gene expression. They
are produced initially by RNA Polymerase 2 (Pol2) as immature transcripts and
are processed into shorter, mature miRNAs (43,44). Mature miRNAs target
messenger RNAs (mRNAs) for inhibition through specific binding at the 3’
untranslated region (UTR), triggering mRNA degradation or halting translation
depending on complementarity (45). Unlike miRNA, other noncoding RNAs have
more complicated functions in chromosomal modifications, gene transcription
and translation (46). miRNAs target many genes for inhibition, and databases
have been developed to predict these interactions (47,48,49). Currently, more
than 700 miRNAs have been identified in the human genome and it is estimated
that approximately 30% of the human genome is regulated by miRNAs (50).
From an evolutionary perspective, miRNAs represent another level of control
over cellular events by tightly regulating gene expression (Figure 1.1A).
Therefore, aberrant miRNA expression in disease processes can disrupt normal
cell physiology and mediate pathogenetic processes (51,52). Altered miRNA
expression generally has 2 possibilities: increased miRNA expression inhibits
specific mRNA expression, whereas decreased miRNA expression enhances
specific mRNA expression (Figure 1.1B). In diabetes, altered metabolic events

	
  

10
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
Figure 1.1
Functions and implications of altered microRNA expression in disease states.
(A) At the post-transcriptional level, miRNAs function to regulation gene
expression by targeting mRNAs for degradation or inhibition. (B) Increased
miRNA results in increased inhibition of target genes, often resulting in reduced
protective factors. Decreased miRNA results in decreased inhibition of target
genes, mediating pathogenetic signaling. [Figure adapted from reference #95]
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lead to alterations of gene transcription. Such changes may also lead to changes
in miRNA expression as both are under similar regulation (51).
miRNAs have been silently involved in the pathogenesis of many
diseases. It is only in recent years that the importance of these background
players is beginning to be understood in chronic diabetic complications.
Understanding epigenetic elements, such as miRNA, can yield new therapeutic
strategies.

1.5 microRNAs in diabetic retinopathy
1.5.1 miRNAs involved with vasoactive factors and matrix protein
accumulation
In diabetic retinopathy, several miRNA have been shown to be involved.
Major investigations have been performed with miR-200b and miR-146a. In this
section, several miRNAs related to diabetic retinopathy will be discussed, as well
as the potential therapeutic efficacy of one promising miRNA, miR-200b.
Increased retinal capillary permeability and other changes are mediated
by increased production of specific factors, including VEGF. One miRNA, miR200b, has been shown to regulate VEGF (53). miR-200b is produced from cluster
of human chromosome 1, along with related miRNAs miR-200a and miR-429.
Our laboratory has shown decreased miR-200b in bovine retinal endothelial cells
exposed to high levels of glucose, as well as in retinal tissue of streptozotocininduced (STZ) diabetic rats at 1 month following diabetes induction. Due to loss
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of negative regulation, VEGF expression and retinal permeability were enhanced.
Intravitreal injections of miR-200b were protective by reducing VEGF as well as
vessel permeability (53). Furthermore, miR-200b levels were decreased in
human retinal tissue from diabetic patients compared to non-diabetic patients,
further supporting that loss of miR-200b occurs in diabetic retinopathy and that
restoring miR-200b may be therapeutically useful (Figure 1.2). Interestingly,
another study in a genetic model of type 1 diabetes (BL/65-Ins2 Akita) found
increased miR-200b expression relative to B6 control mice (54). In this model,
increased miR-200b inhibited oxidation resistance 1 (Oxr1), a protective gene
involved in resistance to oxidative stress. These studies differed in diabetic
models (STZ vs. Akita), time points (1 month vs. 8 months), cell types cultured
and studied (endothelial vs. Mueller cells) and as well as in vitro treatment
conditions, which may have accounted for the differences in miR-200b
expression relative to the non-diabetic controls. Nevertheless, it is possible that
altered expression of miR-200b in either direction could have consequences.
Matrix protein accumulation is another important feature contributing to
structural abnormalities and eventual neovascularization (12). miR-146a
regulates FN levels and is downregulated in the retina of the STZ rat model at 1
month of diabetes (55). Furthermore, intra-ocular injection of miR-146a mimic
reduced FN accumulation. miR-320 is downregulated in diabetic retinopathy and
regulates extracellular signal related kinases 1 and 2 (ERK1/2; part of MAPK
pathway) and activation of VEGF, ET-1 as well as FN. Restoring miR-320 may
be protective in diabetic retinopathy by targeting ERK1/2 signalling (56).
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Figure 1.2
Relationship between diabetes, microRNA-200b (miR-200b) and vascular
endothelial growth factor (VEGF). Previous work in our laboratory has
demonstrated that miR-200b is downregulated in diabetes, leading to increased
VEGF expression and increased permeability (44). Intraocular injection of miR200b mimic was found to be effective in reducing VEGF expression and vascular
permeability, demonstrating miR-200b as a potential therapeutic agent. The
understanding into why miR-200b becomes repressed is limited and is the focus
of the current study.
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Likewise, miR-126 is protective by inhibiting vasoactive factor expression, and
loss of miR-126 resulted in increased VEGF levels, insulin-like growth factor
(IGF)-2 and hypoxia- inducible factor-1 alpha (HIF-1α) (57). These factors play a
major role in late- stage proliferative diabetic retinopathy by further mediating
permeability changes and ECM protein accumulation, which eventually contribute
to neovascularization and vision loss (4).

1.5.2 Therapeutic potential
Overall, miRNAs are important mediators of vascular permeability, matrix
protein accumulation and neovascularization, which together can contribute to
vision loss over time in diabetic patients. Of all the miRNAs described, miR-200b
may have the greatest therapeutic potential for its regulation on VEGF.
Administration of exogenous miR-200b may be efficacious in the treatment of the
microvascular events of diabetic retinopathy, however there are several
limitations. Most obviously, miRNAs are endogenous small interfering RNAs
(siRNAs), and the current use of siRNAs as a therapy is limited only to
experimental purposes (58). While siRNAs and miRNAs offer compelling
therapeutic targets, little is understood about their safety, and the multitude of
potential interactions could be a double-edged sword in disease management
(59). Furthermore, although endogenous delivery mechanisms are being
investigated, miRNAs have short half-lives in circulation and thus would have to
be injected directly into the eye to treat a disease such as diabetic retinopathy,
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offering no logistical advantage to current therapies (60). Instead, identifying a
large molecule (ie. protein) which regulates these miRNAs may be a more
attractive therapeutic strategy.
Understanding into why miRNAs, like miR-200b, become dysregulated in
diabetes is important to further our understanding of the disease, as well as
identify molecular targets that may be important from a therapeutic perspective.
Additional research in this topic is necessary, and current research suggests an
epigenetic link between microRNA regulation and histone methylation.

1.6 An epigenetic connection: histone methylation
Histone modification is another emerging theme in the field of epigenetics
and is involved in the coordination of gene expression. Amino acid residues
within histone subunit molecules become modified in a variety of ways (ie.
acetylation, methylation, phosphorylation etc.), by chromatin modifying enzymes,
which changes the overall accessibility of chromatin and affects how transcription
factors can activate/repress genes in the modified area (61). For example,
acetylation can be thought of as an “activating mark,” as areas of the genome in
which histones are highly acetylated show high gene expression (62,63). The
addition of an acetyl group is thought to make the chromatin more positively
charged and thus more accessible for transcriptional machinery. Methylation is
another histone modification process involved in gene expression but is more
complicated and not as well understood as acetylation (64).
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There are several key principles to keep in mind when discussing histone
methylation. First, the amino acid which is methylated is important. Depending on
the amino acid residue, the result can be activation or repression of gene
expression in that area of the genome (65,66). For example, tri-methylation at
lysine 4 on histone subunit 3 (H3K4me3) is typically activating, leading to
recruitment of transcription factors and increased expression of genes.
Conversely, tri-methylation at lysine 27 on histone subunit 3 (H3K27me3) is
typically repressing, leading to closed chromatin.
Second, existing methyl-marks can be recognized. Chromatin-modifying
enzymes are able to recognize existing marks on histones with high specificity
(67). For example, the recruitment of Polycomb Repressive Complex 2 (PRC2), a
repressing histone methyltransferase complex, to a region of the genome is
inhibited by existing H3K4, H3K36 methylation, H3K27 acetylation or H3K28
phosphorylation (68). Past histone modification can therefore affect future
genomic interaction between other modifying enzymes.
Third, methyl-marks can be removed. Histone methylation is a reversible
and dynamic process and there are many histone demethylases for each type of
methylation (69). For example, Lysine-specific Demethylase 6A (KDM6A) and 6B
(KDM6B) catalyze the demethylation of H3K27me3 and thus oppose or balance
the activity of PRC2 (70). This reversibility of histone methylation adds to the
complexity of interactions but allows for a more attractive therapeutic strategy.
Finally, methyltransferases often complex with adaptor proteins or long
non-coding RNA (lncRNA). Methyltransferases achieve specificity to regions of
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the genome by associating with adaptor proteins and lncRNA. For example,
Supressor of Zeste 12 (SUZ12) and Embryo Ectoderm Development (EED) are
adaptor proteins that interact with Enhancer of the Zeste Homolog 2 (EZH2) to
form PRC2, the major methyltransferase complex for H3K27 methylation. EED
and SUZ12 allow for PRC2 recruitment to specific parts of the genome, which
can be direct through complex protein structures or indirect through lncRNA
(68,71). LncRNA are able to guide chromatin-modifying enzymes to specific
genes through their polar structure; in which one end integrates within the gene
and the free end recruits the enzyme (46). Similarly, lncRNA can act as
molecular scaffolds to increase interactions between transcription factors and
other chromatin modification enzymes.
Research into the expression and activity of histone methyltransferases is
booming in the cancer field and is becoming attractive in the diabetes field due
the recently described phenomena of “metabolic memory.” Changes in gene
expression and resultant vessel functionality due to hyperglycemia have been
observed to persist long after returning to a normoglycemic state (72). So far only
H3K4 and H3K9 methylation have been examined in cell culture studies and
animal models of diabetes. However, evidence suggests that methylation is
indeed a therapeutically targetable mechanism in chronic diabetic complications
(73,74,75,76).
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1.7 Polycomb Repressive Complex 2
One particular type of methylation, H3K27me3, has been linked to miRNA
regulation in several investigations. PRC2 is a repressing histone
methyltransferase complex that has been linked to negatively regulating many
genes, including miRNAs. In this section, the structure and function of PRC2 will
be discussed, as well as potential regulatory relationships that may be of interest
in diabetic retinopathy.

1.7.1 Structure and Function of PRC2
PRC2 is a multimeric complex that catalyzes trimethylation of lysine 27 on
histone H3 (H3K27me3). This is a repressing type of methylation which leads to
closed and inaccessible chromatin (77,78). Thus, PRC2 is believed to be a
negative regulator of gene expression. The complex is composed of a
methyltransferase portion, adaptor proteins, as well as lncRNA, which function in
unison to regulate gene expression. Arguably the most important subunit is
EZH2, which catalyzes the H3K27 trimethylation reaction (78). EZH2 has been
extensively studied in human cancers and is responsible for alterations in tumour
vasculature and invasiveness (79,80). Two other subunits of particular
importance are EED and SUZ12. Unlike EZH2, EED and SUZ12 do not have
direct methyltransferase catalytic function but instead are responsible for
recruitment of EZH2 to different promoter regions (81,82). Specificity to different
regions of the genome is mediated by direct protein-DNA interactions, as well as
by recruitment through lncRNA, such as ANRIL or HOTAIR (83). These lncRNA
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function as molecular flags to direct PRC2 to specific genome areas. They may
also act as scaffolds to bring together chromatin remodeling complexes. Thus,
the methyltransferase function of PRC2 is mediated by EZH2 while its specificity
is mediated by EED and SUZ12, as well as lncRNA.
Most of the functional importance of PRC2 has come from research in the
cancer field. In a variety of cancers, PRC2 components such as EZH2 and
SUZ12 are over expressed, leading to increased H3K27me3 at a variety of gene
promoters. The functional result is silencing of expression in that area, resulting
in increased angiogenesis and enhanced metastasis (84). Furthermore,
increased expression of this complex has been shown be induced by VEGF.
PRC2 is known to negatively regulate vasoinhibin-1 (VASH1), an anti-angiogenic
factor, and can thus further enhance the angiogenic action of VEGF (79,85).
Finally, PRC2 has been implicated in regulating cell-cell adhesion and
inflammatory genes in endothelial cells (86).

1.7.2 PRC2 and microRNA regulation
PRC2, and specifically the EZH2 and SUZ12 subunits, have been shown
to regulate several microRNA in the context of neoplasia. Interestingly, there is
an overlap of several microRNAs, which are repressed both in diabetic
complications and cancer (87). For example, miR-200b is important in the
context of diabetic retinopathy for its regulation on VEGF, which mediates
increased permeability in the eye and eventual neovascularization as the disease
progresses (53). miR-200b is also implicated in several cancers (88). In cancer,
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miR-200b is known as tumour suppressor gene that becomes downregulated or
mutated in cancer (88). This loss of inhibition leads to increased expression of
target genes, which mediates increased tumour invasiveness. In human
fibroblasts, increased H3K27me3 was found at the promoter regions of the miR200 gene cluster with correlating decreased expression relative to epithelial cells,
illustrating a mechanism for how miR-200b becomes repressed (89).

1.8 Rationale
While there is limited understanding as to why microRNAs like miR-200b
become repressed in diabetic complications, based on the above discussion, it is
possible that the underlying regulation of miR-200b may involve PRC2 (Figure
1.3). Altogether, the importance of miR-200b in diabetic retinopathy, with
possible links of PRC2 to miR-200b, provides clear rationale for investigating this
complex in the context of diabetic retinopathy. Involvement of PRC2 in diabetic
retinopathy remains elusive, as well as links to VEGF and angiogenesis,
providing additional motivation for the current study.

1.9 Hypothesis
We hypothesize that glucose induces increased PRC2 expression and
activity, which causes alteration of miR-200b levels. Such changes may play a
role in the development of diabetic retinopathy.
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Figure 1.3
Schematic showing our working hypothesis. (A) Glucose-induced increased
PRC2 expression and activity causes alteration of miR-200b levels. Such
changes may play a role in the development of diabetic retinopathy. (B) This
relationship is hypothesized to be regulated at the level of genome by PRC2mediated repression through H3K27me3 at the miR-200b promoter region.
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1.10

Specific Aims

To test our hypothesis, we have devised 4 objectives:
1. To investigate the effect of glucose on VEGF levels in human retinal
microvascular endothelial cells.
2. To investigate the effect of glucose on PRC2 levels and activity in human
retinal microvascular endothelial cells.
3. To investigate whether PRC2 components are altered in retinal tissues of
diabetic animals.
4. To investigate the regulatory relationship between PRC2 and miR-200b.
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Chapter 2: Materials and Methods
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2.1 In Vitro Studies
2.1.1 Human Retinal Microvascular Endothelial Cells
To investigate PRC2 and miR-200b regulation in the context of diabetic
retinopathy, the major cell type used for investigation was the human retinal
microvascular endothelial cell (HRMECs, Olaf Pharmaceuticals, Worchester,
MA).
HRMECs were grown and passaged in tissue culture flasks in Endothelial
Basal Medium 2 (EBM-2; Lonza, Walkersville, MD) containing 5mM D-glucose,
10% fetal bovine serum (FBS; Sigma-Aldrich, Oakville, ON) and all provided
growth factors and antibiotics (EBM-2 Single Quots). No additional antibiotic was
added to the medium. HRMECs were incubated at 37°C with 5% CO2 and used
between passages 3 and 8 to minimize variability. Prior to experimentation,
HRMECs were seeded on the appropriate dish based on the assay. At 80-90%
confluency, HRMECs were serum starved overnight by removing the growth
medium and replacing it with EBM-2 containing 0% FBS, no growth factors or
antibiotics. Serum starvation is important to remove the confounding variables
(growth factors) in serum. Following starvation, cells were treated with additional
D-glucose (Sigma-Aldrich, Oakville, ON) to represent high glucose levels (HG,
25mM) with normal glucose controls (NG, 5mM). Osmotic controls were also
used where necessary (20mM L-glucose + 5mM D-glucose). All experiments
were performed with 6 replicates unless noted otherwise.
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2.1.2 Human Dermal Microvascular Endothelial Cells
While HRMECs are the focus of most of the work in this study, other
endothelial cell types were investigated to elucidate whether genes associated
with PRC2 might be specific to retinal endothelial cells. Furthermore, human
dermal microvascular endothelial cells (HDMECs) have been used to model
diabetic vascular complications by our laboratory and others.
HDMECs isolated from non-diabetic individuals (Lonza) and type 1 and
type 2 diabetic individuals (Lonza) were cultured identically to HRMECs.
HDMECs from non-diabetic individuals were isolated from adult foreskin and
were pooled together from multiple donors. HDMECs of type 1 diabetes origin
(type 1) were isolated from a 62-year-old female type 1 diabetic patient with a
body-mass index (BMI) of 22. HDMECs of type 2 diabetes origin (type 2) were
isolated from a 73-year-old female type 2 diabetic patient with a BMI or 29.

2.2 In Vivo Studies
Male Sprague–Dawley rats (175 g, 6 weeks old) were obtained (Charles
River, Wilmington, MA, USA). Diabetes was induced by a single intraperitoneal
injection of streptozotocin (STZ, 65mg/kg, in citrate buffer 5.6pH), with control
rats receiving an identical volume of citrate buffer. Rats were monitored for
changes in body weight and blood glucose. After 4 weeks of diabetes duration,
rats were sacrificed, retinal tissue was collected and RNA was extracted as
described below. All animal experimentation was carried out in accordance to
Western University and Animal Care and Veterinary Services Guidelines.
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Male C57BL/6 mice (23-36gm, were administered three doses STZ
(50mg/kg) to induce diabetes, with control animals receiving an identical volume
of citrate buffer. Animals were monitored for changes in body weight and blood
glucose. After 8 weeks of diabetes duration, mice were sacrificed and retinal
tissue was collected.

2.3 RNA Extraction and Real Time RT-PCR
mRNA was extracted using techniques already established in our lab.
Briefly, cells were collected in of TRIZOLTM reagent (Invitrogen, Burlington, ON).
0.2mL of chloroform was added to the tube containing TRIZOLTM, vortexed
vigorously. The samples were centrifuged at 15,000 × g for 15 minutes at 4°C
and the aqueous layer was carefully recovered in a fresh tube. An equal volume
of isopropanol was added to the aqueous layer. The mixture was vortexed briefly,
and centrifuged at 15,000 × g for 15 minutes at 4°C. The pellet was washed with
75% ethanol, dried, resuspended in DEPC water and quantified with
spectrophotometry (260nm; Gene Quant, Pharmacia Biotech, USA).
To generate cDNA, 2µg of total RNA was used with the High Capacity
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and random
hexamer primers. Quantitative Real time RT-PCR was performed using a Roche
LightCycler 96 (Roche, Laval, QC) and SYBR Green detection (Clontech,
Mountain View, CA). The reaction mixture (total volume 20µL) consisted of the
following components: 10µL of SYBR Advantage qPCR Premix, 1µL of each
10µM forward and reverse primer, 1µL cDNA sample and 7µL nuclease free

	
  

30
water. Primers for VEGF, EZH2, EED, SUZ12, KDM6A, and KDM6B are shown
in Table 2.1 (Qiagen, Germantown, MD and Sigma-Aldrich). Normalization was
performed to β-actin to account for differences in reverse transcription
efficiencies of cDNA.

2.4 miRNA Extraction and Real Time RT-PCR
To isolate miRNA, mirVana microRNA Isolation Kit (Ambion, Austin, TX)
was used. Cells were collected using and centrifuged at 200 × g for 4 minutes.
The cell pellet was washed, transferred to a centrifuge tube and spun at 2600 × g
rpm for 4 minutes. The pellet was resuspended in 500µL of lysis buffer. 50µL of
miRNA Homogenate Additive was added to the lysate and the samples were left
on ice for 10 minutes. Five hundred µL of Acid-Phenol:Chloroform (1:1) was
added to the lysate and the mixture was vortexed. The mixture was centrifuged
at 15,000 × g for 10 minutes at 4°C to separate the organic and aqueous layers.
The aqueous layer was carefully removed and transferred to a fresh tube. Six
hundred twenty five µL of 100% ethanol was added to the aqueous layer and the
mixture was vortexed briefly. The mixture was filtered through a filter column in
600µL batches, each time discarding the filtered solution following centrifugation.
Sixty µL of preheated (95°C) Elution Solution was added to the filter column and
the filter was centrifuged for 1 minute in a fresh tube. The RNA concentration
was quantified using spectrophotometry (260nm).
To generate cDNA, 100ng of total RNA was used with Reverse
transcription was performed using the High Capacity Reverse Transcription Kit.
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Table 2.1 Oligonucleotide sequences RT-PCR
Genes
β-actin (human/rat/mouse)

Primer Sequences (5′ à 3′)

EZH2 (human)

CCTCTATGCCAACACAGTGC
CATCGTACTCCTGCTTGCTG
GAACTTTCTGCTGTCTTGGG
CTTCGTGATGATTCTGCCCT
QIAGEN (QT00054614)

EED (human)

QIAGEN (QT00074627)

SUZ12 (human)
KDM6A (human)

TACGGCTCCTATTGCCAAAC
TGCTTCAGTTTGTTGCCTTG
QIAGEN (QT00094654)

KDM6B (human)

QIAGEN (QT00098742)

VASH1 (human)

GTTCCCTCCGAAACTGAGAC
ACAAAGCACCCCCATCTAAC
GCACACTGCAGAAAGATCCA
AGGTAGCACGGACACTGCTT
AGACGTCCAGCTCCTCTGAA
CATCCTCAGTGGGAACAGGT
CTGGCAAAATGGAGGATGAT
GGTCAGTGTTGTGCATTTGG
GTCTCAGGGGTTCCAAAACA
ACACTGCCTGTTCCAAATCC

VEGF (human)

EZH2 (rat)
EZH2 (mouse)
EED (rat/mouse)
SUZ12 (rat/mouse)
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Specific primers are necessary to analyze mature miRNAs due to their short size.
The RT-primer extends the template to create a suitable amplicon length for PCR
analysis. TaqMan miRNA Assays (Applied Biosystems) were used as primers for
Real Time RT-PCR (Table 2.2). miR-200b expression was quantified using this
method and normalization was performed to house keeping gene U6.

2.5 Chromatin Immunoprecipitation (ChIP) qPCR Analysis
To elucidate changes in chromatin modifications associated with high
glucose, ChIP-qPCR was performed. This technique allows pull down of specific
protein targets and confirms genome association by performing qPCR with
primers against select genomic regions. Chromatin Immunoprecipitation (ChIP)
Assay Kit (Milipore, Temecula, CA) was used according to manufacturer’s
instructions. Following 24 hours of glucose exposure, the cells were fixed using
formalin. The plates were incubated at 37°C for 10 minutes and were
immediately removed and washed twice with D-PBS. Five mL of D-PBS
containing protease inhibitors was added to the plate and cells were carefully
suspended using a cell lifter. The D-PBS mixture was transferred to a 15mL tube.
An additional 5mL of D-PBS containing protease inhibitors was added to the
plate to remove any remaining cells. The cells were centrifuged at 200 × g for 4
minutes, and the pellet was washed once with D-PBS, transferred to a 1.7mL
tube and recentrifuged to produce a pellet. The pellet was resuspended in 200µL
of SDS lysis buffer containing protease inhibitors (Roche) and incubated on ice
for 30 minutes, with brief vortexing at 10 minute intervals. The lysate was

	
  

33
Table 2.2 RT-PCR TaqMan miRNA Probe Sequences
Genes
mature miR-200b
U6

	
  

Probe Stem-Loop Sequence (5′ à 3′)
CCAGCUCGGGCAGCCGUGGCCAUCUUACUGGGCAG
CAUUGGAUGGAGUCAGGUCUCUAAUACUGCCUGGU
AAUGAUGACGGCGGAGCCCUGCACG
GTGCTCGCTTCGGCAGCACATATACTAAAATTGGAAC
GATACAGAGAAGATTAGCATGGCCCCTGCGCAAGGAT
GACACGCAAATTCGTGAAGCGTTCCATATTTT
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sonicated on ice three times in 30 second intervals with a KONTES MicroUltrasonic Cell Disruptor (power of 6 at a tuning of 4) to attain DNA fragments in
the 200-1000bp range, appropriate for immunoprecipitation. The lysate was
centrifuged at 18,000 × g for 10 minutes to remove any insoluble cellular
components and the supernanent was transferred to a fresh tube. The
supernatent was precleared using Salmon Slurry Agarose for 30 minutes at 4°C
with rotation. The mixture was briefly centrifuged for 1 minute at 100 × g and was
transferred to a fresh tube. Eighty µL (5%) of each sample was transferred to a
fresh tube and stored at -80°C for an input measurement. For each
immunoprecipitation reaction, 1.6mL of each sample was used and extra sample
discarded. Four µL of antibody (1:400 dilution) was used for each
immunoprecipiation reaction. Antibody-chromatin mixture was incubated
overnight at 4°C with rotation.
Following 14 hours of rotation, 60µL of Salmon Slurry Agarose was added
to each sample and the mixture was incubated for 1 hour at 4°C with rotation.
The mixture was then centrifuged at 100 × g for 2 minutes and the agarose pellet
was washed and re-centrifuged three times at 4°C (1. Low Salt Solution, 2. High
Salt Solution, 3. Li-Cl Solution) and twice at room temperature (both 8.0 pH
EDTA). Each wash was performed for 5 minutes with rotation. Following the final
wash and centrifuge, precipitated DNA was released using 250µL of freshly
prepared elution solution (1% SDS, 1M NaHCO3) rotating for 15 minutes at room
temperature. This elution was repeated to assure effectiveness, for a 500uL
eluate final volume. Twenty µL of 5M NaCl solution was added to the eluate and
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the samples were incubated at 65°C for 4 hours to reverse cross-links. Following
this incubation, 31.5µL of protease K inhibitor solution (Sigma-Aldrich) was
added and incubated for 1 hour at 45°C to degrade proteins. Following this
incubation, 500µL of phenol:cholorform (1:1) was added to each sample. The
samples were vortexed vigorously for 30 seconds and centrifuged at 16,000 × g
for 10 minutes at room temperature. The aqueous layer was carefully removed,
transferred to a new tube, and 1.0mL of 100% ethanol and 150µL of 3M sodium
acetate was added to each sample to induce DNA precipitation. The samples
were mixed by inversion and were left in -20°C.
After 12 hours, DNA was precipitated by centrifuging at 16,000 × g for 10
minutes at 4°C. The supernatant was carefully removed. The pellet was washed
once with 70% ethanol, re-centrifuged and dried. The pellet was resuspended in
8.0 pH EDTA for use in subsequent qPCR analysis.
Pulldown antibodies include anti-H3K27me3 and anti-Pol2 (Milipore).
Control for these antibodies include IgG and ascitic fluid negative control. Primer
design to the miR-200b promoter region was performed based on an identified
promoter region 2kb upstream of the miR-200b gene (Sigma-Aldrich). Control
primers provided by the manufacturer were used to assure the quality of the
ChIP reaction, as well as to determine specificity of the chromatin modification
changes associated with high glucose. Sequences for these primers are listed in
Table 2.3.
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Table 2.3 Oligonucleotides for ChIP-qPCR Analysis
Genomic region
miR-200b promoter
Human alpha satellite
GAPDH promoter

	
  

Primer Sequences (5′ à 3′)
GCCGGGATCACATTCCTC
CTCAGCTTGGGAAAATCCAG
CTGCACTACCTGAAGAGGAC
GATGGTTCAACACTCTTACA
TACTAGCGGTTTTACGGGCG
TCGAACAGGAGGAGCAGAGAGCGA
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2.6 PRC2 inhibition with 3-Deazaneplanocin A (DZNep) chemical inhibitor
A general methylation inhibitor DZNep (Cayman Chemical, Ann Arbor,
MI), which has shown selectivity for PRC2 and H3K27me3, was used as a lossof-function treatment (80). DZNep is an indirect inhibitor of methylation, which
functions by directly inhibiting a hydrolase that metabolizes Ado-Hcy. Ado-Hcy is
a end product formed after a methyltransferase, like EZH2, uses its substrate,
Ado-Met, to methylate an amino acid or nucleotide residue (50). DZNep therefore
results in increased cellular levels of Ado-Hcy, which inhibits EZH2 by moving it
to an inactive conformation. Concentrations from 1µM to 10µM have been shown
to inhibit H3K27me3 activity and 5µM was used for these experiments (90).
DZNep was initially dissolved in DMSO at a concentration of 10mM and
was aliquoted for future use. DZNep was tested in normal glucose and high
glucose, with an equal amount of DMSO (Santa Cruz Biotechnology, Santa Cruz,
CA) as a control in the same conditions. Cells were pre-treated with DZNep at
the starvation period, prior to addition of D-glucose, as well as during the Dglucose treatments.

2.7 PRC2 gene knockdown with small interfering RNA
To improve the specificity of the hypothesized mechanism, knockdown of
specific gene targets was performed using small interfering (siRNA). Specifically,
EZH2 and SUZ12 siRNA (Qiagen) were used for gene knockdown with control
siRNA to control for the transfection process and specificity (Table 2.4).
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Table 2.4 Silencing small interfering RNA sequences
Gene
Control Primers

siRNA sequences (5′ à 3′)
Life Technologies (AM4635)

EZH2

CCAUGUUUACAACUAUCAATT
UUCAUACUUCUAAACAUGGTT
GCAUAAUGUCAAUAGAUAAT
UUAUCUAUUGACAUUAUGCTA

SUZ12

	
  

39
Based on previous experiments in our laboratory, Lipofectamine was used
in the following ratio based on past experiments in our laboratory (2.5µL
Lipofectamine:1µg siRNA) with a final concentration of 100nM. To prepare this,
siRNA and Lipofectamine 2000 (Invitrogen) was first mixed individually in OptiMEM (Life Technologies) containing reduced serum and no antibiotics. After five
minutes, the individual solutions were combined, mixed by inversion, allowed to
settle for 30 minutes. Cells were grown to 80% confluency and were washed with
D-PBS prior to transfection to remove antibiotics. One mL of Opti-MEM
containing siRNA was added to cells. The cells were transfected for 4 hours and
was supplemented with 2x the volume of full EBM-2 containing 10% FBS, growth
factors and antibiotics. 24 hours later, the full medium was replaced with serumfree EBM-2 containing no growth factors or antibiotics and the cells were starved
overnight. 18 hours later, cells were treated with D-glucose and were incubated
for 48 hours, when they were collected for gene expression analysis as
described above. Knockdown efficiency was measured by RT-PCR.

2.8 Tube Formation Assay
As a measure of VEGF activity and angiogenesis, a tube formation assay
was performed with transfected cells. BD Matrigel Matrix Phenol Red-Free (BD
Biosciences, Bedford, MA) was aliquoted (100µL per well) into a 96-well plate.
The plate was spun briefly to remove bubbles and was incubated for 1 hour at
37°C. Prior to seeding, the transfected cells were collected with trypsin and
cellular density was quantified using a hemocytometer. Once the Matrigel

	
  

40
solidified, cells were seeded at a density of 1.5x104 cells per well. Density of cells
plated was determined empirically. The cells were then incubated for 1 hour at
37°C to allow for attachment, after which medium was aspirated and replaced
with serum-free medium containing 25mM (HG) D-glucose. Cells transfected
with control siRNA were also cultured in 5mM (NG) D-glucose as a control. The
plate was then returned to 37°C to allow for tube formation. After 16 hours, the
medium was carefully aspirated from each well, the cells were washed once with
D-PBS and pictures were taken at 40× magnification using a Nikon Diaphot
microscope (Nikon Canada, Mississauga, ON) with PixeLINK camera and
PixeLINK Capture OEM software (PixeLINK, Ottawa, ON). Branch numbers and
branch points were counted and a ratio of branches:branch points was calculated
for each treatment. Each treatment was repeated in triplicate with at least two
field of views per replicate.

2.9 Cell Viability Assay
To determine the cytotoxicity of the treatments used in our experiments,
the WST-1 Cell Viability Assay (Roche) was used. Cells were seeded
(5.0x104/well) onto a 96-well plate and were allowed to attach overnight. The
following morning, the full medium was removed and was replaced with 100µL of
serum-free medium containing various concentrations of D-glucose (5mM,
10mM, 15mM, 25mM, 50mM, 100mM) and various concentrations of DZNep
(50nM, 500nM, 5µM, 50µM, 500µM) with DMSO as a control
(0.0005%,0.005%,0.05%,0.5%,5% v/v). Following 24 hours of incubation with the
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agent, 10µL of WST-1 reagent was added to each well. The plate incubated for
1.5 hours at 37°C to produce a colour reaction. Absorbance was measured with
a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) at 450nm
with a reference wavelength of 690nm. Survival was determined by the
difference between the absorbances at 450nm and 690nm.

2.10 Statistical analysis
To determine statistical significance, 2-tailed Student’s T-test was
performed with an α-value of 0.05 using SPSS. P values < 0.05 were considered
stastically significant (*). For experiments with multiple groups, one-way ANOVA
was performed with an α-value of 0.05 using SPSS. Tukey’s test was performed
to determine differences between groups, with bars represented by different
letters represented a significant difference, while a common letter denotes
groups that are not significantly different.
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Chapter 3: Results
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3.1 High levels of glucose increase VEGF expression in HRMECs
Based on previous experiments performed in our laboratory with different
endothelial cell types, specific concentrations and time points for glucose
exposure were selected for in vitro analysis. However, since the human retinal
microvascular endothelial cell (HRMEC) type is a relatively a new model in our
laboratory, experiments were performed to confirm whether glucose increase
VEGF levels. We show that VEGF mRNA levels was significantly increased after
24 hour exposure to medium containing 25mM glucose compared to 5mM
glucose, while concentrations greater than 25mM did not show any differences in
VEGF expression levels (Figure 3.1). The 25mM D-glucose exposure also
showed decreased cell viability compared to 5mM D-glucose (Figure 3.2).
Therefore, 5mM glucose was selected as normal glucose (NG) and 25mM
glucose was selected as the high glucose (HG) for all subsequent analyses.
These findings are consistent with previous studies performed in our laboratory
using various endothelial cell types.
To test the effects of glucose at different time points, HRMECs were
exposed to 5mM or 25mM D-glucose for various durations. VEGF transcript
levels were significantly increased in HG compared to NG at 24 hour and 48
hours time points, though no significant changes were observed before these
time points (Figure 3.3). Therefore, subsequent experiments were performed at
these time points to test the effects of glucose exposure on endothelial cells.
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Figure 3.1
Real time RT-PCR analysis of VEGF mRNA at different concentrations of
glucose. HRMECs exposed to various concentrations of D-glucose for 24 hours
exhibited differential mRNA levels of VEGF. Compared to 5mM D-glucose, VEGF
expression was significantly increased at 15mM and 25mM D-glucose
concentrations. VEGF was not increased at concentrations higher than 25mM. [*
p < 0.05 compared to 5mM control; n=4; data expressed as mean ± SEM,
normalized to β-actin and expressed as a fold change of 5mM]
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Figure 3.2
WST-1 cell survival assay at different glucose concentrations. HRMECs exposed
to increasing concentrations of D-glucose for 24 hours exhibited decreased cell
viability as measured by a WST-1 assay. Compared to 5mM D-glucose, cell
viability was significantly decreased at 25mM, 50mM and 100mM. [* p < 0.05
compared to 5mM control; n=4; data expressed as mean ± SEM]
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Figure 3.3
Real time RT-PCR analysis of VEGF mRNA levels at different durations of
glucose exposure. HRMECs exposed to 25mM (high glucose; HG) glucose for 24
and 48 hours demonstrated significantly increased VEGF mRNA compared to
5mM (normal glucose; NG). These differences were not observed at time points
earlier than 24 hours. [* p < 0.05 compared to NG; n=4; data expressed as mean
± SEM, normalized to β-actin and expressed as a fold change of NG within each
time point]
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3.2 miR-200b and VEGF are altered in human retinal endothelial cells
exposed to high levels of glucose
To verify the effects of glucose exposure on miR-200b expression,
HRMECs were exposed to 25mM D-glucose for 24 and 48 hours. An equimolar
L-glucose treatment (osmotic control; OSM) was also used. L-glucose is
metabolically inactive and does not cause oxidative stress and hyperglycemiainduced signaling changes as D-glucose does (91,92). At both 24 and 48 hours,
miR-200b levels showed significant decrease in HG compared to NG and OSM
controls (Figure 3.4A). In parallel, VEGF showed significantly increased levels in
HG compared to NG and OSM controls (Figure 3.4B). This result is consistent
with previous work performed in our laboratory in bovine retinal endothelial cells.
This is the first time miR-200b decrease has been observed in human endothelial
cells isolated from the retina. This finding further strengthens the relationship
between hyperglycemia and decreased miR-200b expression in the context of
diabetic retinopathy.

3.3 PRC2 components are altered in endothelial cells exposed to high
glucose levels
Once decreased miR-200b and increased VEGF was established in
HRMECs exposed to HG, the mRNA levels of several genes associated with the
PRC2 complex was measured by qPCR. These included EZH2, the
methyltransferase portion of PRC2, EED and SUZ12, the adaptor protein of
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Figure 3.4
Real time RT-PCR analysis of miR-200b (A) and VEGF (B) in HRMECs exposed
to 5mM D-glucose (NG) 25mM D-glucose (HG) and 20mM L-glucose+5mM Dglucose (osmotic control; OSM). HRMECs cultured for 24 hours and 48 hours in
HG showed significantly decreased levels of miR-200b with parallel increased
levels of VEGF expression compared to NG and OSM. [* p < 0.05 compared to
NG; n=6; data expressed as mean ± SEM, normalized to β-actin and expressed
as a fold change of NG].
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PRC2, and KDM6A and KDM6B, which are the demethylases associated with
H3K27me3 and thus oppose PRC2 activity.
At both 24 and 48 hours in HG, mRNA of EZH2, EED and SUZ12 were
elevated compared to NG and OSM controls (Figure 3.5). These observations
show increased expression of the PRC2 components, which were hypothesized
to negatively regulate miR-200b expression. Thus, this finding supports the
hypothesis by correlating the increased expression of the PRC2 components with
the decrease in miR-200b.
Furthermore, no difference was observed in expression levels of KDM6A
and KDM6B between NG, HG and OSM controls (Figure 3.6). Interestingly,
KDM6A was observed to significantly decrease in HG at the 48 hour time point
(Figure 3.6A). This suggests there is no change or even a decrease in
demethylase expression for H3K27 methylation. Altogether, an increase in
expression of PRC2 with no change or decrease in demethylase expression
suggests a shift towards increase of H3K27me3 in HG. Overall, these
experiments provide correlational evidence linking PRC2 to negatively regulating
miR-200b in HG, though additional supporting evidence is necessary.

3.4 PRC2 activity is increased specifically at the miR-200b promoter region
To demonstrate the involvement of PRC2 at the level of the genome and
chromatin modifications, ChIP was performed using antibodies for H3K27me3.
Negative control antibody IgG was used to demonstrate specificity of the
immunoprecipitation reaction. RNA Polymerase 2 (Pol2) was also
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Figure 3.5
Real time RT-PCR analysis of PRC2 components in HRMECs exposed to 5mM
D-glucose (NG), 25mM D-glucose (HG), and 20mM L-glucose+5mM D-glucose
(OSM). After 24 and 48 hour exposure to D-glucose, levels of EZH2, EED and
SUZ12, were significantly increased compared to NG and OSM controls. [* p <
0.05 compared to NG; n=6; data expressed as mean ± SEM, normalized to βactin and expressed as a fold change of NG].
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Figure 3.6
Real time RT-PCR analysis of demethylases for H3K27me3 in HRMECs
exposed to 5mM D-glucose (NG), 25mM D-glucose (HG), and 20mM Lglucose+5mM D-glucose (OSM). After 24 exposure to D-glucose, KDM6A and
KDM6B levels did not change in HG. After 48 hours, KDM6A was significantly
decreased compared to NG and OSM controls, while KDM6B showed no
change. [* p < 0.05 compared to NG; n=6; data expressed as mean ± SEM,
normalized to β-actin and expressed as a fold change of NG].
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immunoprecipitated to measure transcriptional activity of miR-200b at the level of
the genome in addition to the RT-PCR results demonstrated above. Ascitic was
used as a negative control for this antibody as provided by the manufacturer.
Following immunoprecipitation and qPCR analysis, H3K27me3 was found
to be significantly increased at the miR-200b promoter region in HG compared to
NG controls (Figure 3.7). IgG isotype control pull down showed significantly less
association than the H3K27me3-specific antibody. Also, Pol2 was found to be
significantly decreased at the miR-200b promoter region in HG compared to NG
controls (Figure 3.8). Again, specificity of this antibody was demonstrated as
association with the negative control was minimal. Therefore, this increase of the
H3K27me3, which is specific to the PRC2 complex, demonstrates a strong
regulatory relationship between PRC2 and miR-200b at the level of chromatin
modification. Furthermore, since this type of methylation is believed to be
repressing and is associated with closed chromatin, the observation of
decreased Pol2 association at the miR-200b promoter region further supports the
mechanism and accounts for the decrease in miR-200b expression
demonstrated earlier in this project. Altogether, these results paint a picture of
the genomic events occurring at the miR-200b promoter region in HG, and
further support that PRC2 may regulate miR-200b in diabetes.
Finally, to improve the specificity of this mechanism, areas of the genome
with well-known association to the targets that were immunoprecipitated were
measured by qPCR. No significant differences were observed in H3K27me3 and
Pol2 association at the α-satellite region and GAPDH promoter region between
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Figure 3.7
ChIP-qPCR analysis of H3K27 trimethylation (H3K27me3) at the miR-200b
promoter region. Association of H3K27me3 at the miR-200b promoter region was
significantly increased in 25mM (HG) glucose compared to 5mM (NG) glucose.
Association of IgG negative control antibody was minimal and showed no
difference between NG and HG. [* p < 0.05 compared to NG; n=3; data
expressed as mean percentage of input ± SEM].
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Figure 3.8
ChIP-qPCR analysis of RNA polymerase 2 (Pol2) at the miR-200b promoter
region. Association of Pol2 at the miR-200b promoter region was significantly
decreased in 25mM (HG) glucose compared to 5mM (NG) glucose. Association
of ascitic fluid (negative control) was minimal and showed no difference between
NG and HG. [* p < 0.05 compared to NG; n=3; data expressed as mean
percentage of input ± SEM].5
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NG and HG, though specificity between the specific and non-specific antibodies
was still observed (Figures 3.9 and 3.10). These negative control experiments
further support that PRC2 specifically regulates miR-200b in HG, as these
changes in H3K27me3 and Pol2 association are specific to certain genomic
regions and are not global.

3.5 Loss of function analysis using DZNep inhibitor demonstrates a causeand-effect relationship between PRC2 and miR-200b expression
To demonstrate a cause-and-effect relationship between PRC2 and miR200b, a chemical inhibitor for H3K27me3, DZNep, was used. Prior to
experimenting with DZNep, the potential toxicity of different concentrations of
DZNep was measured using a WST-1 cell viability assay. Compared to DMSO
control, DZNep showed increased survival at all concentrations (Figure 3.11).
Significantly increased toxicity was observed at 500µM DZNep and 5% DMSO.
The concentration of 5µM was selected for further studies.
HRMECs treated for 24 hours with DZNep showed significantly higher
miR-200b levels in both NG and HG compared to the other controls (Figure
3.12A). In parallel, VEGF mRNA was significantly decreased when HRMECs
were treated with DZNep compared to all other controls (Figure 3.12B). Since
PRC2 was hypothesized to negatively inhibit miR-200b, through its repressing
methylation-mark, increased expression of miR-200b would be expected by
inhibiting PRC2. Increased miR-200b expression was observed with decreased
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Figure 3.9
ChIP-qPCR analysis of H3K27 trimethylation (H3K27me3) at the human alphasatelite region. Association of Pol2 at the human alpha satellite region showed no
significant change between 25mM (HG) glucose and 5mM (NG) glucose.
Association of IgG negative control antibody was minimal and showed no
difference between NG and HG. [* p < 0.05 compared to NG; n=3; data
expressed as mean percentage of input ± SEM].
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Figure 3.10
ChIP-qPCR analysis of RNA polymerase 2 (Pol2) at the GAPDH promoter
region. Association of Pol2 at the GAPDH promoter region showed no significant
difference between 25mM (HG) glucose and 5mM (NG) glucose. Association of
ascitic fluid (negative control) was minimal and showed no difference between
NG and HG. [* p < 0.05 compared to NG; n=3; data expressed as mean
percentage of input ± SEM].
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Figure 3.11
WST-1 cell viability assay shows that HRMECs exposed to 3-Deazaneplanocin A
(DZNep) for 24 hours increased in viability compared to an equivalent
concentration of DMSO. [* p < 0.05 compared to DMSO control; n=4; data
expressed as mean ± SEM].
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Figure 3.12
Real time RT-PCR analysis of miR-200b and VEGF levels in HRMECs treated
with 3-Deazaneplanocin A (DZNep) in 25mM (HG) glucose or 5mM (NG)
glucose). After 24 exposure to DZNep in NG and HG, miR-200b levels were
significantly increased with parallel decreased levels of VEGF compared to
controls. [NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM Dglucose + 0.05% DMSO, HG+DMSO= 25mM D-glucose + 0.05% DMSO,
NG+DZNEP = 5mM D-glucose + 5µM DZNep, HG+DZNEP = 25mM + 5µM
DZNep; identical letters represent groups that are not significantly different; p <
0.05; n=6; data expressed as mean ± SEM, normalized to β-actin for VEGF and
U6 for miR-200b, expressed as a fold change of NG].
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VEGF mRNA, a target of miR-200b, providing evidence to support the hypothesis
by showing a cause-and-effect relationship by using loss-of-inhibition.

3.6 Loss of function with siRNA demonstrates that SUZ12 is of importance
in PRC2-mediated regulation of miR-200b
To further eludicate the role of specific components of PRC2 in the
regulation of miR-200b, siRNA-mediated gene knockdown of EZH2 and SUZ12
was performed. Control siRNA was used as a negative control. Knockdown
efficiency was verified by RT-PCR and efficacy was verified by measuring the
transcript levels of a known target of PRC2 (Figures 3.13 and 3.14). In HG,
HRMECs transfected with control siRNA showed a significant decrease in miR200b expression and increase in VEGF expression (Figure 3.15). When EZH2
was silenced in HG, miR-200b and VEGF showed no differences in expression
compared to HRMECs treated with control siRNA in HG (Figure 3.15). However,
silencing of SUZ12 increased miR-200b and decreased VEGF, with levels similar
to HRMECs transfected with control siRNA in NG (Figure 3.15). In addition, a
tube formation assay was conducted to provide a functional correlate. HRMECs
transfected with control siRNA and EZH2 siRNA in HG showed significantly
increased branching compared to HRMECs transfected with control siRNA in NG
(Figure 3.16). HRMECs treated with SUZ12 siRNA in HG showed decreased
branching, equivalent to HRMECs treated with control siRNA in NG (Figure
3.16). Altogether, this data suggests that SUZ12 is important in regulating miR200b in HG, as knockdown of SUZ12 corrected miR-200b and VEGF levels.
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Figure 3.13
Real time RT-PCR analysis of EZH2 and SUZ12 in HRMECs transfected with
control or specific siRNA. When cultured in 25mM (HG) glucose, HRMECs
transfected with EZH2 siRNA showed significantly decreased levels of EZH2
compared to HRMECs transfected with control siRNA. Furthermore, HRMECs
transfected with SUZ12 siRNA showed significantly decreased levels of SUZ12
compared to HRMECs transfected with control siRNA. [* p < 0.05 compared to
HG+control siRNA; n=6; data expressed as mean ± SEM, normalized to β-actin
and expressed as a fold change of HG+control siRNA].
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Figure 3.14
Real time RT-PCR analysis of VASH1 in HRMECs exposed to 25mM (HG)
glucose with EZH2 or SUZ12 siRNA. VASH1 mRNA levels were significantly
increased in HRMECs transfected with EZH2 and SUZ12 siRNA compared to
HRMECs transfected with control siRNA. [* p < 0.05 compared to HG+control
siRNA; n=6; data expressed as mean ± SEM, normalized to β-actin and
expressed as a fold change of HG+control siRNA].

	
  

76

VASH1:β-actin (Fold change)

VASH1
3

	
  *
	
  *

2

1

0
HG+control
siRNA

	
  

HG+EZH2 siRNA

HG+SUZ12
siRNA

77

Figure 3.15
Real time RT-PCR analysis of miR-200b and VEGF levels in HRMECs
transfected with EZH2 or SUZ12 siRNAs after 48 hour exposure to 25mM (HG)
glucose or 5mM (NG) glucose). In HRMECs transfected with EZH2 siRNA in HG,
miR-200b and VEGF expression was not significantly different from HG+control
siRNA but decreased compared to NG+control siRNA. In HRMECs transfected
with SUZ12 siRNA in HG, miR-200b was significantly increased with parallel
decreased levels of VEGF compared to HRMECs transfected with control siRNA,
with levels similar to NG+control siRNA. [NG+control siRNA = 5mM D-glucose +
100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control
siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12
siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that
are not significantly different; p < 0.05; n=6; data expressed as mean ± SEM,
normalized to U6 or β-actin and expressed as a fold change of NG+control
siRNA].

	
  

78

miR-‐200b	
  

A
miR-‐200b:U6	
  (Fold	
  change)	
  

1.5	
  

a
a

1	
  

b

b

0.5	
  

0	
  
NG+control	
   HG+control	
   HG+EZH2	
  
siRNA	
  
siRNA	
  
siRNA	
  

VEGF

B

b

VEGF:β-actin (Fold change)

1.5

a
1

HG+Suz12	
  
siRNA	
  

b

a

0.5

0
NG+control HG+control HG+EZH2 HG+Suz12
siRNA
siRNA
siRNA
siRNA

	
  

79

Figure 3.16
Tube formation assay as a measure endothelial branching in HRMECs
transfected with various siRNA. 1.5×104 were seeded on top of Matrigel and
incubated for 16 hours at 37°C to assess tubule formation. HRMECs transfected
with HG+control siRNA demonstrated significantly increased branching
compared to NG+control siRNA. Transfection of EZH2 siRNA did not reduce
endothelial branching significantly compared to HG+control siRNA. However,
transfection of SUZ12 siRNA significantly reduced endothelial branching
compared to HG+control siRNA. [NG+control siRNA = transfected with 100nM
control siRNA and incubated for 16h in 5mM D-glucose following seeding,
HG+control siRNA = transfected with 100nM control siRNA and incubated for
16h in 25mM D-glucose following seeding, HG+EZH2 siRNA = transfected with
100nM EZH2 siRNA and incubated for 16h in 25mM D-glucose following
seeding, HG+SUZ12 siRNA = transfected with 100nM SUZ12 siRNA and
incubated for 16h in 25mM D-glucose following seeding; identical letters
represent groups that are not significantly different; p < 0.05; n=3 biological
replicates with 2 fields of view each; data expressed as mean ± SEM].
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3.7 PRC2 involvement in other endothelial cell types and in target tissues
of diabetic complications
Finally, the expression of PRC2 components was measured in retinal
tissues of animal models of diabetes. We used streptozotocin-induced (STZ) rat
and mouse models. All clinical data on these models is previous published
(93,94). We used RNA isolated from retinal tissues of these models to determine
whether changes seen in retinal endothelial cells are also present in vivo. EZH2,
EED and SUZ12 were significantly increased in the retinal tissue of diabetic
animals compared to non-diabetic controls (Figure 3.17). This finding is
consistent with the in vitro data produced in this project and suggests that PRC2mediated regulation of miR-200b may be relevant in vivo.
Furthermore, the expression of PRC2 components was measured in
human dermal microvascular endothelial cells isolated from healthy individuals
(HDMECs), from a patient with type 1 diabetes (Type 1) and a patient with type 2
diabetes, all treated in NG or HG. Significantly increased expression of PRC2
was observed in all cell types treated in HG (Figure 3.18). This suggests that
PRC2 may be relevant in endothelial cells and may not be specific to retinal
endothelial cells. This opens up the exciting possibility of common pathogenic
mechanisms in diabetic complications.
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Figure 3.17
Real time RT-PCR analysis of PRC2 component expression in animal retinal
tissue from streptozotocin (STZ) induced diabetic and control animals. After 1
month of diabetes, EZH2, EED and SUZ12 levels were increased in rat retinal
tissue from diabetic animals compared to control animals. After 2 months of
diabetes, EZH2, EED and SUZ12 levels were increased in mouse retinal tissue
of diabetic animals compared to controls. [* p < 0.05 compared to control; n=6;
data expressed as mean ± SEM, normalized to β-actin and expressed as a fold
change of control].
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Figure 3.18
Real time RT-PCR analysis of PRC2 components in human dermal
microvascular endothelial cells (HDMECs) of various origins. In non-diabetic
adult HDMECs, EED and SUZ12 levels were significantly increased by HG. In
HDMECs isolated from patients with diabetes (Type 1 & Type 2), EZH2, EED
and SUZ12 were significantly increased in HG compared to NG controls.
[HDMECs = human dermal microvascular endothelial cells, Type 1 = HDMECs
isolated from a patient with type 1 diabetes, Type 2 = HDMECs isolated from a
patient with type 2 diabetes; * p < 0.05 compared to NG; n=6; data expressed as
mean ± SEM, normalized to β-actin and expressed as a fold change of NG].
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Discussion
Our key findings are: 1) miR-200b and VEGF are altered in HRMECs
exposed to glucose, 2) PRC2 component mRNA and activity at the miR-200b
promoter region is in HRMECs exposed to glucose, 3) treatment with DZNep
inhibitor and transfection of SUZ12 siRNA increased miR-200b and decreased
VEGF levels, and 4) PRC2 components are altered in retinal tissues from
diabetic animals and other endothelial cell types exposed to high glucose.
Histone methylation as a mechanism for a dynamic response to external stimuli,
like hyperglycemia, is a new way of thinking. Few mediators and types of
methylation have been studied in the context of diabetic complications thus far.
H3K27 methylation research has been expanding in the cancer field but remains
uninvestigated in diabetes. Furthermore, recent evidence from cancer research
suggests that the major methyltransferase complex for H3K27 trimethylation,
PRC2, is involved in silencing several miRNA involved in cancer, including miR200b. Since miR-200b is also involved in diabetic retinopathy, a similar
underlying mechanism may be present and is worth investigating.
HRMECs exposed to high glucose levels typically seen in diabetes
showed decreased miR-200b with parallel increased VEGF. As mentioned
earlier, there has been some controversy over the directionality of whether miR200b becomes repressed or overexpressed in diabetic retinopathy. Different
investigations have found conflicting results, although differences in animal
model choice and cell culture conditions may account for this (95). Never the
less, replicating miR-200b repression in high glucose conditions was an
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important starting point in this study and verified results produced previously in
our laboratory. Furthermore, this investigation showed repressed miR-200b in a
relatively new cell type, which was isolated from human retina. This further
strengthens the relevance of this in vitro model to the in vivo disease, as organspecific signaling is sometimes apparent in diabetes (ie. not all organs respond in
the same manner to hyperglycemia). Therefore, this cell type was chosen for all
subsequent experiments for its relevance to the organ of interest.
Establishment of correlational evidence between miR-200b repression and
PRC2 was important to first investigating a potential regulatory relationship.
Though many proteins and lncRNA are involved in the PRC2 complex, three
major components were selected for investigation. EZH2 is the major
methyltransferase component while EED and SUZ12 are the major adaptor
proteins. Expression of the major PRC2 components was increased in HG.
Furthermore, this increase was specific to D-glucose treatment but not L-glucose.
This suggests that PRC2 expression is increased due to signaling induced by
hyperglycemia, and not simply due to osmolarity changes. This could be due to
induction of certain transcription factors. For example, hypoxia inducible factor 1
alpha (HIF-1α) has been shown to become stabilized and increase in
transcriptional activity by high glucose in brain endothelial cells (96).
Furthermore, HIF-1α has been shown to regulate EZH2 and may be responsible
for regulating others genes in the PRC2 complex (97,98). Further investigation
into HIF-1alpha stabilization would be suggest as a possible upstream
mechanism of PRC2 induction in hyperglycemia.
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Interestingly, after 24 hours of glucose exposure, no change was
observed in the demethylases for H3K27me3, KDM6A and KDM6B.
Furthermore, after 48 hours of glucose treatment, KDM6A was decreased
relative to NG controls, while KDM6B again showed no change. Although
increased mRNA expression of PRC2 components, and no change or decrease
in KDM6A/B mRNA, does not imply a direct increase in their activity, it does
suggest that PRC2 activity may be increased through increased expression.
Further investigating these components at the protein level would strengthen this
relationship between high glucose and increased PRC2 expression.
Most importantly, H3K27me3 was increased in HG specifically at the miR200b promoter region, just upstream of the transcriptional start site. This increase
in H3K27 methylation, a repressing type of methylation, suggests formation of
closed, inaccessible chromatin and accounts for the decreased expression of
miR-200b. Since PRC2 mediates this type of methylation, this observation further
strengthens the hypothesis that PRC2 regulates miR-200b in response to
hyperglycemia. Furthermore, RNA Pol2 association at the same promoter region
was decreased in HG, further suggesting that heterochromatin was formed and
that decreased expression of miR-200b in HG is regulated at the genome level.
Finally, these changes in qPCR appear to be specific to the miR-200b promoter
region. At the human alpha-satelite region, an area of heterochromain well
known to associate with H3K27me3, no changes were observed in H3K27me3.
Also, at the GAPDH promoter region, a highly expressed area of the genome, no
changes were observed in Pol2 association. Therefore, H3K27me3 is increased
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specifically, while Pol2 association is decreased specifically, at the miR-200b
promoter region. This is one of the first investigations to connect two epigenetic
mechanism, ie. histone methylation and microRNAs, in the context of a
complication of diabetes. While there is no doubt that PRC2 regulates other
genes, miR-200b is one gene that becomes repressed in response to PRC2
induction in HG.
ChIP-qPCR is a powerful technique for elucidating changes in chromatin
modifications and transcriptional machinery recruitment. However, ChIP-qPCR is
limited in the range of which changes can be determined because primers must
be designed to specific regions. By combining ChIP with DNA sequencing (ChIPseq), a greater overall picture of the genomic landscape can be mapped,
providing information on how the overall miR-200 gene is affected, as well as if
H3K27me3 affects other genes.
Cause-and-effect experimentation was important to further demonstrating
a regulatory relationship between PRC2 and miR-200b. Using a chemical
inhibitor of PRC2 and H3K27me3, DZNEP, miR-200b expression was
significantly increased while VEGF was decreased in parallel. DZNep is not
specific for H3K27me3 inhibition, thus siRNA-mediated gene knockdown was
used to further elucidate the mechanism (90). siRNA against EZH2 and SUZ12
were used because these targets have been directly linked to regulating miR200b in neoplasia. Interestingly, silencing of EZH2 in HG showed no significant
changes in miR-200b and VEGF levels when compared to control siRNA.
However, in HG, silencing of SUZ12 produced significantly increased miR-200b
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and decreased VEGF expression compared to control siRNA, and similar
expression to control siRNA in NG. Furthermore, silencing of SUZ12 produced
decreased endothelial branching compared to control siRNA and EZH2 siRNA,
indicating functional alterations in endothelial cells and possibly a proxy of VEGF
action. Therefore, it is possible that PRC2 regulation is dependent on SUZ12 and
not EZH2. This is interesting because EZH2 is the major methyltransferase
component for PRC2 and has been demonstrated to regulate miR-200b in
neoplasia. EZH2 is often regarded as the most important component for PRC2
regulation, however in our study SUZ12 was shown to be important for miR-200b
regulation. One possibility is that silencing of EZH2 in HG is insufficient to
restore miR-200b levels to normal levels because SUZ12 is still able to occupy
the miR-200b promoter region. Studies have shown that recruitment of PRC2 is
dependent on SUZ12 (82,83,99). Furthermore, EZH1, a homolog of EZH2, also
catalyzes for H3K27me3 and has been shown to compensate for EZH2knockdown by replacing it in PRC2 complex (100,101). Thus, silencing of SUZ12
prevents methylation at the miR-200b promoter region by preventing overall
recruitment of PRC2, while silencing of EZH2 may be compensated by EZH1.
Although EZH1 was not examined in this investigation, it may explain why SUZ12
appears to be important in PRC2-mediated regulation of miR-200b. Additional
experimentation is necessary to elucidate the interplay of these specific
components of PRC2.
Finally, additional correlational evidence using other models, including
animal models and other endothelial cell types, suggests the potential
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importance of PRC2 in diabetic retinopathy. In retinal tissue from diabetic rats
and mice EZH2, EED and SUZ12 expression was increased relative to nondiabetic control animals. Therefore, this mechanism may be relevant in vivo and
requires further investigation to determine the therapeutic potential of inhibiting
these targets to prevent the microvascular changes associated with diabetes.
Furthermore, PRC2 components were elevated in HDMECs exposed to HG
isolated from healthy individuals, as well as individuals with type 1 and type 2
diabetes. This further strengthens the mechanism that PRC2 components are
elevated in HG in endothelial cells. Furthermore, the increase in HG observed in
endothelial cells isolated from diabetic patients offers some interesting
conclusions. These cells were isolated from patients who had diabetes for
several years (ie. greater than 20 years). However, when treated in HG, PRC2
components were still overexpressed suggesting that hyperglycemia-induced
upregulation does not become dampened. Thus, PRC2 and miR-200b may be
important in other complications of diabetes.
Many different experiments were performed to elucidate this regulatory
mechanism. One major limitation is that most of this work was done at the
RNA/transcript level. Since this project was focused on determining expression
changes at the level of the genome, RT-PCR was chosen as the major technique
used to show changes. While expression at the RNA and protein levels are often
parallel, replication of the changes at the protein level, such as by using Western
Blotting or ELISA, would further strengthen the results. Furthermore, the
knockdown efficiency between EZH2 and SUZ12 siRNA transfections differed
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slightly, which may also explain why EZH2 silencing was ineffective in elevating
miR-200b levels while SUZ12 silencing was effective. Finally, tube formation
assay was used as a proxy of VEGF activity. Direct testing using ELISA or other
techniques, such as a permeability assay, would further strengthen these results.
None-the-less, the battery of experiments performed suggests increased PRC2
expression and activity at the miR-200b promoter region, providing rationale for
why miR-200b becomes repressed in diabetes.
While other work in the field of epigenetics in diabetic complications has
focused on either histone methylation or miRNAs, this project has shown how
these epigenetic mechanisms work together to regulate VEGF. This project has
demonstrated that PRC2 negatively regulates miR-200b and thus appears to be
a good therapeutic target in diabetic retinopathy. Due to its nature as a
multimeric enzyme complex, it can potentially be targeted with a small molecule.
While much work is needed to design a chemical inhibitor that would selectively
target this complex and be effective in being transported to the retina, an organ
with its own selective permeability, this work has demonstrated another
therapeutic strategy, which may show efficacy in the prevention of diabetic
retinopathy. It is hoped that continued investigation into this complex will lead to
a small molecule therapy for diabetic retinopathy that can be more accessible
and cost effective in treating diabetic retinopathy, though such goals are far in the
distance.
In summary, we show that PRC2 regulates miR-200b in retinal endothelial
cells through H3K27me3 repression (Figure 4.1). This is one of the first
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investigations to connect histone methylation and miRNA regulation in the
context of diabetic retinopathy. Ultimately, this work builds on the
characterization of miRNA our lab has studied by elucidating a new regulation
mechanism. Investigating such mechanisms is important to further our
understanding of the signaling events that occur in response to hyperglycemia in
diabetic retinopathy, as well as developing novel treatment strategies to maintain
the quality of life of patients with diabetes.
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Figure 4.1
Summary diagram of key findings. Findings of this study demonstrate a
regulatory relationship between PRC2 and miR-200b, of which SUZ12 appears
to be the most important component in mediating this regulation (indicated by *).
PRC2 is increased by high glucose, leading to repression of miR-200b and
subsequently causing a loss-of-inhibition on VEGF levels. Altered VEGF
production can lead to increased vascular permeability and neovascularization in
diabetic retinopathy, demonstrating potential importance of PRC2 as a
therapeutic strategy.
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Future Directions
To further determine the efficacy of PRC2 inhibition in the prevention of
microvascular changes in diabetic retinopathy, an in vivo model of diabetes
would be suggested. Intraocular injection of diabetic rats with SUZ12 siRNA
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appears to be the most effective in the study of this complex in diabetic
retinopathy, based on the in vitro results. Furthermore, while the linear regulation
of PRC2, miR-200b and VEGF was focused on in this project, PRC2 and miR200b have been demonstrated in other studies to regulate genes of relevance in
diabetic retinopathy. For example, PRC2 has been demonstrated to regulate
VASH1, an anti-angiogenic factor. Inhibition of PRC2 may lead to increased
VASH1, which may be desirable to prevent permeability changes and
neovascularization associated with diabetic retinopathy (79,85). Also, miR-200b
has been shown to regulate p300, a histone acetyltransferase associated with
activation of matrix protein expression in diabetic retinopathy (53). Thus, while
PRC2 was demonstrated to regulate miR-200b directly and VEGF indirectly in
diabetic retinopathy, many potential interactions may be relevant. This highlights
the importance of this complex in diabetic retinopathy as a therapeutic target.
Additional experimentation in this area could further strengthen the potential
therapeutic efficacy of PRC2 inhibition in diabetic retinopathy.
Finally PRC2 has numerous interactions with lncRNA, which opens up the
possibility for future research into an extremely novel field. LncRNA (ie. HOTAIR)
act as molecular scaffolds and may mediate other interactions with histone
remodeling complexes (102). Furthermore, lncRNA (ie. ANRIL) act as
recruitment flags for PRC2 to mediate specific association to genome regions
(83). Investigations into these lncRNA in parallel with PRC2 may reveal a more
complex interplay of epigenetic factors which together coordinate gene
regulation.
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